Answer
Sativex is indicated for symptom improvement in adults with moderate to severe spasticity due to multiple sclerosis who have responded inadequately to other anti-spasticity medication and demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.
Sources for this answer
- Sativex Oromucosal SpraySVX Therapeutics Limited · emc · SmPC §4.1 Therapeutic Indications · Version 9Document updated
Sources checked